BACKGROUND AND PURPOSE: Survivors of aneurysmal subarachnoid hemorrhage (SAH) may have an increased risk of cardiovascular events because of shared risk factors. We compared incidences of vascular diseases, vascular death, and all-cause death after SAH with those in the general population. METHODS: From the Swedish Hospital Discharge and Cause of Death registries, we identified patients with SAH between January 1987 and January 2003. Conditional on survival of 3 months after SAH, we calculated standardized mortality and incidence ratios with corresponding 95% CIs for vascular death, all-cause death, and fatal or nonfatal vascular diseases. Cumulative risks were estimated with survival analysis. RESULTS: Of 17,705 patients with SAH (mean age, 59.7 years; 59.5% women), 11,374 survived at least 3 months after SAH. During follow-up (mean, 6.8 years), 2152 (18.9%) died. The risk of death was 12.9% within 5 years, 23.6% within 10 years, and 35.4% within 15 years after SAH. The overall standardized mortality ratio was 1.57 (95% CI, 1.44 to 1.70) for vascular death and 1.61 (95% CI, 1.52 to 1.70) for all-cause death. The standardized mortality ratios were particularly high in younger individuals, ranging from 2.1 to 3.7 for vascular death and from 2.1 to 2.6 for all-cause death for patients between 50 and 65 years of age. The standardized incidence ratio for fatal or nonfatal vascular diseases was 1.51 (95% CI, 1.45 to 1.56). CONCLUSIONS: Mortality and risk of vascular diseases are increased in survivors of SAH. Prevention of new vascular diseases after SAH by management of risk factors seems important.
BACKGROUND AND PURPOSE: Survivors of aneurysmal subarachnoid hemorrhage (SAH) may have an increased risk of cardiovascular events because of shared risk factors. We compared incidences of vascular diseases, vascular death, and all-cause death after SAH with those in the general population. METHODS: From the Swedish Hospital Discharge and Cause of Death registries, we identified patients with SAH between January 1987 and January 2003. Conditional on survival of 3 months after SAH, we calculated standardized mortality and incidence ratios with corresponding 95% CIs for vascular death, all-cause death, and fatal or nonfatal vascular diseases. Cumulative risks were estimated with survival analysis. RESULTS: Of 17,705 patients with SAH (mean age, 59.7 years; 59.5% women), 11,374 survived at least 3 months after SAH. During follow-up (mean, 6.8 years), 2152 (18.9%) died. The risk of death was 12.9% within 5 years, 23.6% within 10 years, and 35.4% within 15 years after SAH. The overall standardized mortality ratio was 1.57 (95% CI, 1.44 to 1.70) for vascular death and 1.61 (95% CI, 1.52 to 1.70) for all-cause death. The standardized mortality ratios were particularly high in younger individuals, ranging from 2.1 to 3.7 for vascular death and from 2.1 to 2.6 for all-cause death for patients between 50 and 65 years of age. The standardized incidence ratio for fatal or nonfatal vascular diseases was 1.51 (95% CI, 1.45 to 1.56). CONCLUSIONS: Mortality and risk of vascular diseases are increased in survivors of SAH. Prevention of new vascular diseases after SAH by management of risk factors seems important.
Authors: Jin Seub Hwang; Min Kyung Hyun; Hyun Joo Lee; Ji Eun Choi; Jong Hee Kim; Na Rae Lee; Jin-Won Kwon; EnJu Lee Journal: BMC Neurol Date: 2012-09-22 Impact factor: 2.474
Authors: Gurbey Ocak; Rianne Boenink; Marlies Noordzij; Willem Jan W Bos; Bjorn E Vikse; Aleix Cases; Julia Kerschbaum; Jaakko Helve; Maurizio Nordio; Mustafa Arici; Lucile Mercadal; Christoph Wanner; Runolfur Palsson; Kristine Hommel; Johan De Meester; Myrto Kostopoulou; Rafael Santamaria; Emilio Rodrigo; Helena Rydell; Samira Bell; Ziad A Massy; Kitty J Jager; Anneke Kramer Journal: JAMA Netw Open Date: 2022-04-01
Authors: Chinh Quoc Luong; Hung Manh Ngo; Hai Bui Hoang; Dung Thi Pham; Tuan Anh Nguyen; Tuan Anh Tran; Duong Ngoc Nguyen; Son Ngoc Do; My Ha Nguyen; Hung Dinh Vu; Hien Thi Thu Vuong; Ton Duy Mai; Anh Quang Nguyen; Kien Hoang Le; Phuong Viet Dao; Thong Huu Tran; Luu Dang Vu; Linh Quoc Nguyen; Trang Quynh Pham; He Van Dong; Hao The Nguyen; Chi Van Nguyen; Anh Dat Nguyen Journal: PLoS One Date: 2021-08-13 Impact factor: 3.240